Bacterial Vaccine For Canidae Or Mustelidae (e.g., Dogs, Foxes, Minks, Etc.) Patents (Class 424/828)
-
Patent number: 8993252Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: March 21, 2013Date of Patent: March 31, 2015Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 8911748Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.Type: GrantFiled: May 17, 2013Date of Patent: December 16, 2014Assignee: Boise State UniversityInventor: Juliette Tinker
-
Patent number: 8834898Abstract: The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of Staphylococcus aureus. One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of an antigenic material from S. aureus and an antigenic material from a S. aureus-specific polypeptide.Type: GrantFiled: December 16, 2011Date of Patent: September 16, 2014Assignee: Boise State UniversityInventor: Juliette Tinker
-
Patent number: 7879336Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.Type: GrantFiled: June 23, 2008Date of Patent: February 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Shelly L. Shields, Hans A Draayer, Michael J Huether
-
Patent number: 7138124Abstract: The present invention provides compositions including at least two siderophore receptor polypeptides and at least two porins from a gram negative microbe, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of makino and methods of using such compositions.Type: GrantFiled: June 3, 2003Date of Patent: November 21, 2006Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub, Donavan E. Zammert, Gayla K. Kallevig
-
Patent number: 6936263Abstract: The present invention relates to the use of the major OprI lipoprotein of Pseudomonas aeruginosa to elicit a Type-1 immune response towards a heterologous antigen. The invention relates specifically to the use of OprI—antigen fusion proteins to elicit the Type-1 response. More particularly, the present invention is directed to pharmaceutical formulations comprising OprI and/or OprI fusion proteins, optionally together with a suitable excipient, to stimulate the Th1 dependent, cellular immune response.Type: GrantFiled: August 16, 2002Date of Patent: August 30, 2005Assignee: Vlaams Interuniversitair Instituut voor Biotechnologie VZWInventors: Hilde Revets, Pierre Cornelis, Patrick De Baetselier
-
Patent number: 6589571Abstract: The invention is concerned with a method for combating summer eczema caused by gnats of the species Culicoides pulicolaris and malanders in non-human mammals with a composition for external application which contains components of plants of the species Equisetum.Type: GrantFiled: September 20, 2001Date of Patent: July 8, 2003Inventor: Helmut Koniger
-
Patent number: 6368603Abstract: Disclosed and claimed are compositions containing a Borrelia burgdorferi antigen, and methods for making and using them. The antigen can be OspA. The compositions can contain at least one additional antigen from a pathogen other than Borrelia burgdorferi. The compositions are useful for eliciting an immunological response in a host mammal susceptible to Lyme Disease and to the mammalian pathogen other than Borrelia burgdorferi. Suitable host mammals include dogs, pups, horses, and, the additional antigen can be of a canine, equine or feline pathogen, such as rabies, canine distemper, adenovirus, coronavirus, parainfluenza and parvovirus. No significant efficacy interference is observed.Type: GrantFiled: March 5, 1997Date of Patent: April 9, 2002Assignee: Merial LimitedInventor: Judy Jarecki-Black
-
Patent number: 6355255Abstract: Novel vaccines for use against &bgr;-hemolytic Streptococcus colonization or infection are disclosed. The vaccines contain an immunogenic amount of a variant of strepococcal C5a peptidase (SCP). Also disclosed is a method of protecting a susceptible mammal against &bgr;-hemolytic Streptococcus colonization or infection by administering such a vaccine. Enzymatically inactive SCP, and polynucleotides encoding these SCP proteins are further disclosed.Type: GrantFiled: December 7, 1998Date of Patent: March 12, 2002Assignee: Regents of the University of MinnesotaInventors: Paul Patrick Cleary, Deborah K. Stafslien
-
Patent number: 6316005Abstract: A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi.Type: GrantFiled: January 21, 1997Date of Patent: November 13, 2001Assignee: Solvay Animal Health, Inc.Inventors: Jon B. Korshus, Paul L. Runnels, Richard L. Sharpee, Ronald F. Schell, Steven M. Callister
-
Patent number: 6251405Abstract: Immunological compositions and methods for making and using them. The compositions contain an antigen and a lipoprotein and optionally an adjuvant. The lipoprotein can itself be antigenic or immurogenic. The antigen can be influenza HA and the lipoprotein a recombinantly expressed product having an OspA leader for lipidation and PspA for the protein portion. The antigen can be OspC and the lipoprotein OspA. The components of the composition are co-administered. A potentiated immunological response is obtained by the compositions and methods.Type: GrantFiled: June 7, 1995Date of Patent: June 26, 2001Assignee: Connaught Laboratories, Inc.Inventors: Robert S. Becker, Robert C. Huebner, Maryann B. Gray, Karen S. Biscardi
-
Patent number: 6210676Abstract: An OspC Dra fragment fusion peptide isolated from Borrelia burgdorferi is described herein for the prevention, treatment and early diagnosis of Lyme disease in humans and other animals. This invention also relates to a screening method detecting anti-Osp borreliacidal antibody activity, and antibodies reacting with a protein fragment encoded by a DraI-SmaI DNA fragment of OspC.Type: GrantFiled: July 30, 1999Date of Patent: April 3, 2001Assignee: Gundersen Lutheran Medical FoundationInventors: Steven M. Callister, Steven D. Lovrich, Ronald F. Schell, Dean A. Jobe
-
Patent number: 6019984Abstract: Novel bacterial preparations containing one or more isolated and purified strain of a microorganism which produces one or more RTX toxins, and which strain has at least one RTX toxin which is substantially cell-associated. Methods of preparing the bacterial preparations and their use as vaccines and to produce antibodies for passive immunization are described.Type: GrantFiled: December 23, 1996Date of Patent: February 1, 2000Assignee: University of GuelphInventors: Janet MacInnes, Paul Ricciatti, Bonnie Mallard, Soren Rosendal, deceased
-
Patent number: 5955090Abstract: The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.Type: GrantFiled: December 14, 1995Date of Patent: September 21, 1999Assignee: Chiron Behring GmbH & Co.Inventors: Bernhard Knapp, Klaus-Dieter Hungerer, Michael Broker, Bernd-Ulrich von Specht, Horst Domdey
-
Patent number: 5750112Abstract: This invention provides a vaccine which contains, per dose, an effective immunizing amount of an inactivated feline enteric coronavirus and a suitable carrier. The vaccine of this invention may also contain an adjuvant, an effective immunizing amount of a second inactivated virus and a an effective immunizing amount of an inactivated bacteria. Additionally provided by this invention is a method of immunizing a dog against disease caused by canine coronavirus involving administering to the dog a dose of the vaccine of this invention. The method of this invention may also involve administering one or more additional doses of vaccine to the dog, immunizing the dog against disease caused by a second virus and immunizing the dog against disease caused by a bacteria.Type: GrantFiled: December 8, 1993Date of Patent: May 12, 1998Assignee: Solvay Animal Health, Inc.Inventor: Michael A. Gill